Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 7/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084465 | 0.82 | SLC6A4 (0.44) | SLC6A4MTNR1AMTNR1B | |
| SCHEMBL6084876 | 0.80 | SLC6A4 (0.46) | SLC6A4HTR1A | |
| SCHEMBL6085340 | 0.69 | SLC6A4 (0.48) | SLC6A4RORCHTR1AMTNR1AMTNR1B | |
| SCHEMBL6085348 | 0.69 | SLC6A4 (0.48) | SLC6A4RORCHTR1AMTNR1AMTNR1B | |
| SCHEMBL6085361 | 0.68 | SLC6A4 (0.53) | SLC6A4RORCHTR1ACNR1CNR2 | |
| SCHEMBL6083843 | 0.67 | SLC6A4 (0.46) | SLC6A4MTNR1AMTNR1B | |
| SCHEMBL6636075 | 0.67 | SLC6A4 (0.53) | SLC6A4RORCHTR1ACNR1CNR2 | |
| SCHEMBL6084265 | 0.66 | SLC6A4 (0.56) | SLC6A4RORCHTR1ACNR1CNR2 | |
| SCHEMBL6637786 | 0.66 | SLC6A4 (0.50) | SLC6A4RORCHTR1ACNR1CNR2 | |
| SCHEMBL6084271 | 0.66 | SLC6A4 (0.56) | SLC6A4RORCHTR1ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105516-B2 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | HTR5A, SLC18A2, CYP17A1 | SLC6A4 12/4885RORC 2310/4885HTR1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.